Novartis Positions US Strategy As Defense Against Rising Trade Levies

Vas Narasimhan, CEO of Novartis AG (NYSE:NVS), said the Swiss drugmaker's expanding U.S. manufacturing footprint and a December agreement with the U.S. government could protect it from potential tariffs threatened by the Trump administration.

Speaking at the World Economic Forum in Davos, Narasimhan highlighted Novartis's $23 billion U.S. investment, unveiled last year, as a strategic safeguard that enables the company to supply the U.S. market primarily from domestic facilities. He added that existing stockpiles further cushion the company against near-term trade disruptions.

Trump has ...